Building the future of first-in-class THCA therapeutics
Built to answer
one unexplored
scientific question.
Can purified tetrahydrocannabinolic acid (THCA) be developed into a reproducible, clinically evaluated pharmaceutical candidate for inflammatory disease? THCA Therapeutics is building an evidence-led development program to investigate that question, beginning with rheumatoid arthritis.
Evidence first
Scientific hypotheses are tested through defined analytical, nonclinical and clinical development gates.
Focused development
Our lead program, THCA PURE™ Oral, concentrates resources on an investigational oral candidate.
Pharmaceutical rigor
Quality, reproducibility, safety assessment and regulatory planning guide development.
Patient relevance
We aim to generate interpretable evidence around an important unmet clinical need.
From scientific
curiosity to a
structured
development thesis.
THCA Therapeutics emerged from a question about the therapeutic potential of the unheated acidic cannabinoid THCA. That initial curiosity has evolved into a focused biotechnology development strategy. Personal observations are not treated as clinical evidence.
A question
An early hypothesis about purified THCA and the scientific gaps surrounding it.
An evidence review
Evaluation of published preclinical research and the limitations of existing data.
A lead indication
Rheumatoid arthritis selected as the initial therapeutic development focus.
A growing team
Founder-led operations strengthened by founding scientific leadership and specialist expertise.
A clear mission.
A long-term
scientific vision.
We are developing a specialized, asset-light biotechnology organization built around transparent evidence standards, qualified collaborators and disciplined decision-making.
Investigate THCA through pharmaceutical development.
Advance an investigational purified-THCA program through formulation, analytical, nonclinical and—subject to authorization—clinical research.
Build a specialized biotech company recognized for scientific discipline.
Create development assets grounded in credible science, quality, ethical research and a clear distinction between potential and demonstrated benefit.
Founder-led.
Strengthened by
scientific leadership.
THCA Therapeutics combines entrepreneurial leadership with clinical epidemiology and research-methodology expertise. Its expanding scientific structure is designed to support careful decisions at each stage of development.
Farbod Parvin
Company strategy, development vision and execution.
Farbod founded THCA Therapeutics to explore whether purified THCA can be advanced through a rigorous pharmaceutical-development pathway. He leads company strategy, program priorities, financing and the development of external scientific and manufacturing relationships.
Prof. Joel Gagnier
Clinical epidemiology, research methodology and translational development strategy.
Prof. Joel Gagnier is a clinical epidemiologist and academic researcher with extensive experience in clinical research methodology, evidence synthesis and musculoskeletal health. As Founding Chief Scientific Officer, his remit includes scientific positioning, evidence review, clinical-development strategy, study-design considerations and evaluation of specialist research collaborators.
Academic appointments are independent of THCA Therapeutics; no university sponsorship, affiliation or endorsement is implied.
Transparent about
what is defined—
and what remains
to be proven.
THCA PURE™ Oral is an investigational formulation concept. Published third-party preclinical findings provide a research rationale, not evidence of product-specific human benefit.
Lead focus
Purified THCA, with rheumatoid arthritis as the initial indication.
Development approach
Milestone-based formulation, analytical, nonclinical and regulatory work.
Clinical efficacy
Human therapeutic benefit has not been demonstrated for THCA PURE™ Oral.
Approval & readiness
Clinical authorization, validated product performance and market approval are not claimed.
A focused internal
core supported by
specialist partners.
Leadership retains scientific direction and program oversight while specialist work is planned with appropriately qualified external organizations. Discussions with prospective partners are not represented as contracted engagements.
Scientific strategy
Critical interpretation of evidence and research priorities.
Formulation & CMC
Planned product feasibility, analytical control and manufacturing development.
Nonclinical research
Purpose-built studies and decision gates, as justified by the program.
Clinical development
Protocol strategy, endpoint selection and human studies only after necessary approvals.
Quality & regulatory
Phase-appropriate quality systems, documentation and authority engagement.
Specialist collaboration
Assessment of suitable investigators, CDMOs, CROs and expert advisers.
The principles
behind every
development decision.
Scientific credibility depends as much on the decisions not to advance as on the milestones achieved.
Evidence
Test hypotheses and describe findings at their true level of certainty.
Integrity
Represent scientific, regulatory and company status accurately.
Quality
Prioritize reproducibility, analytical control and patient protection.
Focus
Advance a defined lead program before pursuing wider optionality.
Collaboration
Build relationships around relevant expertise and clear responsibilities.
Scientific humility
Stop, redesign or narrow the program when data do not support advancement.
THCA Therapeutics is an early-stage biotechnology business. THCA PURE™ Oral is investigational and is not an approved medicine. Human safety, efficacy and appropriate dosing have not been established.
